Nils Glenjen

2.4k total citations · 1 hit paper
22 papers, 838 citations indexed

About

Nils Glenjen is a scholar working on Hematology, Surgery and Oncology. According to data from OpenAlex, Nils Glenjen has authored 22 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Surgery and 7 papers in Oncology. Recurrent topics in Nils Glenjen's work include Acute Myeloid Leukemia Research (8 papers), Esophageal Cancer Research and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Nils Glenjen is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Esophageal Cancer Research and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Nils Glenjen collaborates with scholars based in Norway, Sweden and United Kingdom. Nils Glenjen's co-authors include Øystein Bruserud, Anita Ryningen, Bjørn Tore Gjertsen, Magnus Nilsson, Signe Friesland, Gjermund Johnsen, Lars Lundell, Fredrik Klevebro, Ingunn Hatlevoll and Gabriella Alexandersson von Döbeln and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

Nils Glenjen

21 papers receiving 830 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction

2016 273 citations Fredrik Klevebro, Gabriella Alexandersson von Döbeln et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Nils Glenjen

Since Specialization

Citations

This map shows the geographic impact of Nils Glenjen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nils Glenjen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nils Glenjen more than expected).

Fields of papers citing papers by Nils Glenjen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nils Glenjen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nils Glenjen. The network helps show where Nils Glenjen may publish in the future.

Co-authorship network of co-authors of Nils Glenjen

This figure shows the co-authorship network connecting the top 25 collaborators of Nils Glenjen. A scholar is included among the top collaborators of Nils Glenjen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nils Glenjen. Nils Glenjen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging 2023 ·Molecular Oncology ·(unknown), Kjersti Tjensvoll, Satu Oltedal, Ingvild Dalen, Morten Lapin, Herish Garresori, Nils Glenjen, Bjørnar Gilje, Oddmund Nordgård	5
2	Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study 2022 ·BMC Cancer ·Oddmund Nordgård, Morten Lapin, Kjersti Tjensvoll, Satu Oltedal, (unknown), (unknown), (unknown), Herish Garresori, Nils Glenjen, Rune Smaaland, Bjørnar Gilje	2
3	Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial) 2019 ·British journal of surgery ·(unknown), Fredrik Klevebro, Asif Johar, Gjermund Johnsen, (unknown), Nils Glenjen, Signe Friesland, Mats Lindblad, (unknown), Lars Lundell, Pernilla Lagergren, Magnus Nilsson	19
4	Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial 2018 ·Diseases of the Esophagus ·Gabriella Alexandersson von Döbeln, Fredrik Klevebro, (unknown), (unknown), Niels Hilmer Nielsen, Gjermund Johnsen, Ingunn Hatlevoll, Nils Glenjen, Signe Friesland, Lars Lundell, Jingru Yu, Magnus Nilsson	115
5	Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer 2018 ·Journal of Translational Medicine ·Morten Lapin, Satu Oltedal, Kjersti Tjensvoll, (unknown), Rune Smaaland, Herish Garresori, Milind Javle, Nils Glenjen, (unknown), Bjørnar Gilje, Oddmund Nordgård	93
6	Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial 2018 ·Diseases of the Esophagus ·(unknown), Gjermund Johnsen, (unknown), Nils Glenjen, Signe Friesland, Mats Lindblad, Ioannis Rouvelas, N. Wang, Lars Lundell, Pernilla Lagergren, Magnus Nilsson	11
7	PS02.120: NEOADJUVANT CHEMOTHERAPY VERSUS NEOADJUVANT CHEMORADIOTHERAPY FOR CANCER OF THE OESOPHAGUS OR GASTRO-OESOPHAGEAL JUNCTION: LONG-TERM RESULTS 2018 ·Diseases of the Esophagus ·(unknown), Fredrik Klevebro, Anne-Birgitte Jacobsen, Niels Hilmer Nielsen, Gjermund Johnsen, Ingunn Hatlevoll, Nils Glenjen, Signe Friesland, Lars Lundell, Magnus Nilsson	1
8	A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction breakdown → 2016 ·Annals of Oncology ·Fredrik Klevebro, Gabriella Alexandersson von Döbeln, N. Wang, Gjermund Johnsen, Anne-Birgitte Jacobsen, Signe Friesland, Ingunn Hatlevoll, Nils Glenjen, P Lind, Jon A. Tsai, Lars Lundell, Magnus Nilsson	273
9	FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study. 2012 ·Journal of Clinical Oncology ·Nils Glenjen, (unknown), Ingunn Hatlevoll, (unknown), (unknown), Geir Egil Eide, Halfdan Sørbye, Olav Dahl, Gunilla Frykholm	1
10	In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8 2004 ·Leukemia Research ·Anita Ryningen, Line Wergeland, Nils Glenjen, Bjørn Tore Gjertsen, Øystein Bruserud	61
11	In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts 2004 ·International Journal of Cancer ·Nils Glenjen, Elisabeth Ersvær, Anita Ryningen, Øystein Bruserud	14
12	Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels 2004 ·European Journal Of Haematology ·Nils Glenjen, Kimberley Joanne Hatfield, Øystein Bruserud	18
13	In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines 2003 ·Leukemia Research ·Øystein Bruserud, Nils Glenjen, Anita Ryningen, Elling Ulvestad	24
14	Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts 2003 ·European Journal Of Haematology ·Øystein Bruserud, Nils Glenjen, Anita Ryningen	13
15	The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status 2003 ·European Journal Of Haematology ·Nils Glenjen, Randi Hovland, Line Wergeland, Øystein Wendelbo, Peter Ernst, Øystein Bruserud	14
16	Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia 2002 ·International Journal of Cancer ·Nils Glenjen, Knut Anders Mosevoll, Øystein Bruserud	35
17	Interleukin-7 (IL-7) in Patients Receiving Intensive Chemotherapy for Acute Myelogenous Leukemia: Studies of Systemic IL-7 Levels and IL-7 Responsiveness of Circulating T Lymphocytes 2002 ·Journal of Interferon & Cytokine Research ·Øystein Wendelbo, Nils Glenjen, Øystein Bruserud	11
18	A critical review of T cell targeting immunotherapy in pancreatic cancer: only a hypothesis or a real hope for the patients? 2002 ·Expert Opinion on Biological Therapy ·Nils Glenjen, Øystein Bruserud	2
19	Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells 2002 ·Expert Opinion on Biological Therapy ·Øystein Bruserud, Nils Glenjen, Bjørn Tore Gjertsen, Lars Herfindal, Stein Ove Døskeland	5
20	Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. 2002 ·PubMed ·Øystein Bruserud, Tien‐sheng Huang, Nils Glenjen, Bjørn Tore Gjertsen, Brynjar Foss	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact